Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

PLX Protalix BioTherapeutics Inc

0.05 (4.24%)
May 24 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 276,874
Bid Price
Ask Price
News -
Day High 1.24


52 Week Range


Day Low 1.18
Company Name Stock Ticker Symbol Market Type
Protalix BioTherapeutics Inc PLX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 4.24% 1.23 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.18 1.18 1.24 1.23 1.18
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,824 276,874 $ 1.22 $ 337,658 - 1.0308 - 2.505
Last Trade Time Type Quantity Stock Price Currency
20:00:00 26,073 $ 1.23 USD

Protalix BioTherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
90.58M 73.05M - 65.49M 8.31M 0.11 10.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Protalix BioTherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PLX Message Board. Create One! See More Posts on PLX Message Board See More Message Board Posts

Historical PLX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.161.371.131.22404,1210.076.03%
1 Month1.191.371.03081.16528,3150.043.36%
3 Months1.681.681.03081.24422,190-0.45-26.79%
6 Months1.421.901.03081.40347,790-0.19-13.38%
1 Year2.262.5051.03081.75559,670-1.03-45.58%
3 Years2.953.550.701.711,023,035-1.72-58.31%
5 Years0.39617.020.171.97824,7680.8339210.53%

Protalix BioTherapeutics Description

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis.The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Your Recent History

Delayed Upgrade Clock